APOMINE Intermittent apomorphine hydrochloride hemihydrate 30mg/3mL injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

apomine intermittent apomorphine hydrochloride hemihydrate 30mg/3ml injection cartridge

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - apomorphine injection is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

APOMINE apomorphine hydrochloride hemihydrate 100 mg/20 mL solution for infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

apomine apomorphine hydrochloride hemihydrate 100 mg/20 ml solution for infusion vial

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; hydrochloric acid; water for injections - indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

APOWOK apomorphine hydrochloride hemihydrate 10 mg/mL solution for injection or infusion ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

apowok apomorphine hydrochloride hemihydrate 10 mg/ml solution for injection or infusion ampoule

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apowok solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

APO-LEVODOPA/CARBIDOPA 100/25 levodopa 100 mg and carbidopa (as monohydrate) 25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-levodopa/carbidopa 100/25 levodopa 100 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: crospovidone; quinoline yellow aluminium lake; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch - apo-levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. apo-levodopa/carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

APO-LEVODOPA/CARBIDOPA 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-levodopa/carbidopa 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; crospovidone; pregelatinised maize starch; indigo carmine aluminium lake - apo-levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. apo-levodopa/carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

SINADOPA 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sinadopa 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; indigo carmine aluminium lake; crospovidone - sinadopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. sinadopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

SINADOPA 100/25 levodopa 100 mg and carbidopa (as monohydrate) 25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sinadopa 100/25 levodopa 100 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; quinoline yellow aluminium lake; microcrystalline cellulose; crospovidone - sinadopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. sinadopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

SINEMET 250/25 levodopa/carbidopa 250 mg/25 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

sinemet 250/25 levodopa/carbidopa 250 mg/25 mg tablet bottle

organon pharma pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 250 mg - tablet, uncoated - excipient ingredients: indigo blue; maize starch; magnesium stearate; microcrystalline cellulose; pregelatinised maize starch - sinemet is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. sinemet frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

SINEMET 100/25 levodopa/carbidopa 100 mg/25 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

sinemet 100/25 levodopa/carbidopa 100 mg/25 mg tablet bottle

organon pharma pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: quinoline yellow; maize starch; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate - sinemet is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. sinemet frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

DEKINET Israel - English - Ministry of Health

dekinet

rafa laboratories ltd - biperiden hydrochloride - tablets - biperiden hydrochloride 2 mg - biperiden - biperiden - all types of parkinson's disease.